Does Mirabegron the β3 Agonist Frequently Used in the Treatment of Overactive Bladder Really Affect the Respiratory System Negatively ? A Prospective Study

Year 2024, Volume: 2 Issue: 3, 95 - 100, 30.12.2024

Ahmet Cinislioğlu , Adem Utlu , Tugay Aksakalli , Fatih Akkaş , Kadir Ozmen , Ahmet Gedik , Elif Yılmazel Ucar , Ömer Araz , Şenol Adanur

https://doi.org/10.62425/rtpharma.1573724

Abstract

Abstract
Objective
Overactive bladder syndrome (OAB) has been defined by the International Continence Society (ICS) as feeling a sudden urge to urinate that mostly runs its course with increased daytime urination and waking up during the night to urinate. we aimed to contribute to the literature by investigating the effects of mirabegron treatment on the respiratory system in patients diagnosed with OAB.
Methods
The study was conducted on 63 patients diagnosed with OAB.A single dose of 50 mg tablets per day was prescribed to patients diagnosed with OAB to achieve standardization. Treatment was continued for three months. Spirometry and body plethysmography were performed to objectively evaluate the respiratory functions of patients with OAB.
Results
The spirometry and body plethysmography showed that the FVC value was 102.51 ± 16.99 L before, 101.77 ± 14.17 L at the first month, and 100.52 ± 15.98 L at the third month after mirabegron treatment. There was no statistically significant difference between the FVC value before mirabegron treatment and the FVC value measured at the first month after treatment, between the FVC value measured at the first month of treatment and the third month of treatment, and between the FVC values measured before treatment and the third month of treatment (p = 0.805, p = 1.000, p = 1.000, respectively).
Conclusions
Our study results show that mirabegron, a β3 agonist, has no negative effect on the respiratory system in patients diagnosed with overactive bladder.
Keywords: β3 agonist; Mirabegron; Respiratory; Spirometry; Overactive Bladder
Özet
Amaç
Aşırı aktif mesane sendromu (OAB), Uluslararası Kontinans Derneği (ICS) tarafından, çoğunlukla gündüz idrara çıkma ve gece idrara çıkmak için uyanma ile seyrini sürdüren ani bir idrara çıkma dürtüsü hissi olarak tanımlanmıştır. AAM tanısı alan hastalarda mirabegron tedavisinin solunum sistemi üzerine etkilerini araştırarak literatüre katkı sağlamayı amaçladık.
Yöntemler
Çalışma, AAM tanısı alan 63 hasta üzerinde gerçekleştirildi. AAM tanısı alan hastalara standardizasyonu sağlamak amacıyla günde tek doz 50 mg tablet reçete edildi. Tedaviye üç ay devam edildi. AAM'li hastaların solunum fonksiyonlarını objektif olarak değerlendirmek için spirometri ve vücut pletismografisi yapıldı.
Bulgular
Spirometri ve vücut pletismografisinde FVC değerinin mirabegron tedavisi öncesinde 102,51 ± 16,99 L, birinci ayda 101,77 ± 14,17 L, üçüncü ayda ise 100,52 ± 15,98 L olduğu görüldü. Mirabegron tedavisi öncesinde ölçülen FVC değeri ile tedavi sonrası 1. ayda ölçülen FVC değeri arasında, tedavinin 1. ayında ölçülen FVC değeri ile tedavinin 3. ayında ölçülen FVC değeri arasında ve tedavi öncesi ölçülen FVC değerleri arasında istatistiksel olarak anlamlı fark saptanmadı treatment (sırasıyla p = 0.805, p = 1.000, p = 1.000).
Sonuç
Çalışma sonuçlarımız, bir β3 agonisti olan mirabegron'un aşırı aktif mesane tanısı alan hastalarda solunum sistemi üzerine olumsuz bir etkisinin olmadığını göstermektedir.
Anahtar Kelimeler
β3 agonisti; Mirabegron; Solunum; Spirometri; Aşırı aktif mesane

Keywords

β3 agonist, Mirabegron, Respiratory, Spirometry, Overactive Bladder

References

• Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28(4):287.
• Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-6.
• Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649-53.
• Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26(6):752-6.
• Chapple CR, Mironska E, Wagg A, Milsom I, Diaz DC, Koelbl H, et al. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. Eur Urol Focus. 2020;6(3):522-30.
• Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol. 2018;73(4):596-609.
• Song YS, Lee HY, Park JJ, Kim JH. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis. J Urol. 2020:101097ju0000000000001440.
• Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Salvatore S, Serati M. Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;251:73-82.
• Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558-63.
• European Association U. European Association of Urology Guidelines. 2020 Edition. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020.
• Schena G, Caplan MJ. Everything You Always Wanted to Know about β(3)-AR * (* But Were Afraid to Ask). Cells. 2019;8(4).
• Malsin ES, Coleman JM, Wolfe LF, Lam AP. Respiratory dysfunction following initiation of mirabegron: A case report. Respir Med Case Rep. 2019;26:304-6.
• Abe H, Minokoshi Y, Shimazu T. Effect of a beta 3-adrenergic agonist, BRL35135A, on glucose uptake in rat skeletal muscle in vivo and in vitro. J Endocrinol. 1993;139(3):479-86.
• Puzzo D, Raiteri R, Castaldo C, Capasso R, Pagano E, Tedesco M, et al. CL316,243, a β3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength. Sci Rep. 2016;5:37504.
• Miller A, Enright PL. PFT interpretive strategies: American Thoracic Society/ European Respiratory Society 2005 guideline gaps. Respir Care. 2012;57(1):127-33; discussion 33-35.
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6 Suppl 16:5-40.
• Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511-22.